Quality excellence: The next frontier for the Indian pharmaceutical industry



Indian Pharmaceutical Alliance

QUALITY means doing the right thing when no one looking Henry Ford

Indian pharma is a significant contributor to global public health



60% of global vaccine production



annual UNICEF supply globally





60%+ of global supply of ARV drugs

40-70% of

WHO demand for DPT & BCG



90% of WHO demand for measles vaccine

Indian pharma has been able to deliver this impact due to its distinctive capabilities

Manufacturing capabilities

- Highest number of US FDA-registered facilities outside US (379 facilities)
- 1400+ WHO GMP certified plants; 800+ UK MHRA certified sites

Product development capabilities

- 37% of total ANDA approvals
- 22% of the approvals in specialty generics

Process innovation capabilities

One of the world leaders in efficient and cost competitive API manufacturing

Quality in pharma has been an increasing concern, both globally and in India

Between 2008 and 2014, the number of product recalls and warning letters to pharma companies globally tripled

2

At least one pharma facility worldwide has entered into a consent decree every year since 2008 globally



30% of quality related warning letters are attributed to India



10% of OAI inspections and 4% of drug recalls in last 5 years are from India

Indian companies in other sectors have continuously received recognition for Quality excellence

Sector specific accolades

Sample sector	Player	Award	Year
Steel	TATA STEEL	 Deming Grand prize 	2012
Auto components	Expanding Horizons	 Deming Grand Prize 	
Infra-structure	DELHI INDIRA GANDHI DELHI INTERNATIONAL AIRPORT	 #1 airport by size #5 airport by region (Asia Pacific) 	
Aviation	IndiGo	 A320 best operation- al excellence 	

Indian pharma could achieve quality excellence by focusing on six improvement areas

Establishing robust and seamless data management and documentation



Ensuring effective and robust investigations



Aligning management systems with increasing operational complexity

<mark>4</mark>

Expanding and upskilling talent pool



Embedding quality into product development and technology transfer

Building a culture of quality across the organization

Pharmaceutical companies need to take a holistic approach by building 'Quality' into three systems



Potential steps for key stakeholders – individual companies


- Evaluate and upgrade QMS
- Embed quality across product lifecycle

- Embed a culture of quality
- Strengthen the organization with specialist roles
- Develop robust capability building infrastructure



- Harmonize metrics driving accountability and
 - collaboration
- Adopt predictive metrics over and above output metrics
- Scale up governance systems

Potential steps for key stakeholders - IPA




Potential steps for key stakeholders – Government and regulators

 Guide companies and industry bodies by providing feedback on guidelines, benchmarks and training modules under development

 Continue to engage in periodic dialogue to clarify industry's understanding of guidelines, clauses and metrics

The IPA has already begun the journey towards quality excellence



3



IPA commits to being conduit of change in the industry

The start of a long journey ...

Over next 5 years IPA will work to:

- Create targeted guidelines and best practices
- Measure and benchmark Indian pharmaceutical quality with the rest of the world and track progress
- Expand the skill and capability of quality talent for Indian pharmaceutical companies

IPA will develop a 5 year plan, with clear intermediate milestones over the next 12 months. IPA will also review progress annually and further refine the plan periodically

Thank You



Management commitment to 'Quality'



Indian pharma industry's contribution to affordable healthcare



90%+ drugs approved by US FDA for PEPFAR¹



33%+ of all medicines dispensed in US²



USD254 bn

health system savings in US³ by all generics. Significant contribution by India

Millions will die if India cannot produce new HIV/AIDS medicines in the future – it is a matter of life and death⁴ – UNAIDS

Generic medicines have saved the US health system USD 1.7 trillion from 2005 to 2014⁵ - CDER, FDA

The Indian pharmaceutical industry has one of the largest number of manufacturing plants of the international standards



1400 +

WHO GMP certified sites

270 +

PMDA (Japan)

accredited

sites


800+

UK MHRA certified sites

250+

EDQM approved plants

Evolution of the Indian pharmaceutical industry




Inspections of Indian Pharma manufacturing sites by US FDA


Number of inspections went up in 2015



Proportion of OAI + VAI decisions has remained the same




Regulatory actions on Indian pharma manufacturing sites by US FDA



Outstanding 'Quality' creates disproportionate upside


Intent to purchase

~1 million responses in surveys



Industry studies suggest, culture drives 30% of 'Quality' outcomes

Quality outcomes, Percentage of quality lots



Indian players have been able to build a culture of quality and discipline

#1 ranked airport worldwide: Delhi International Airport; in the top 3 for 4 years in a row

Mumbai and Delhi airports are among the **Top 5** airports in Asia-Pacific in terms of Airport Service Quality (ASQ)



10th best in

cumulative air accidents record; ahead of US, UK, and France **Top 3** in Asia with a customer satisfaction score of 8/10

Indigo Airline WON the

Best Operational Excellence Award among 311 airlines; **Top 10** in on-time performance in Asia-Pacific



Leaders in hospitality globally: Oberoi Group and Taj Hotels

Have properties ranked in **Top 10** by **Travel** and Leisure magazine





Management system — Build right leading metrics to predict and correct future quality challenges

Pyramid of leading quality indicators

Correlation coefficients between quality metrics

(Perfect correlation = 1.00)





Certain imperatives arise for all key stakeholders individual companies, IPA and regulatory bodies.

1	Pharma companies	 Diagnose and identify challenges Prioritize based on risk Design and implement solutions, both corrective and preventive
2	Indian Pharmaceuti cal alliance	 Facilitate industry-wide collaboration, like creation of best practices and guidelines Develop training content and industry-wide mechanisms
3	Government and regulators	 Support the industry by providing inputs and feedback on initiatives by industry to ensure quality Create platform for dialogue with pharmaceutical companies on regulations